Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesHuman genome sciences and glaxosmithkline announce positive phase 3 study results for benlysta
Human Genome Sciences, 07/21/09
Human Genome Sciences, Inc. and GlaxoSmithKline PLC announced that BENLYSTA met the primary endpoint in BLISS–52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus. In the placebo–controlled BLISS–52 study, the results showed that belimumab plus standard of care achieved a clinically and statistically significant improvement in patient response rate at Week 52, compared with standard of care alone. Study results also showed that belimumab was generally well tolerated, with adverse event rates comparable between belimumab and placebo treatment groups.
Today in Major Studies...keeping you current
Receive free subspecialty "5-minute updates" via email
In vitro Growth Inhibitory Activity and Malaria Risk in a Cohort Study in Mali
Infection and Immunity, 12/01/09
A Multicenter, Double-Blind, Randomized, Parallel Group Study Comparing Polyvinyl Chloride and Polyvinyl Chloride-Free Catheter Materials
The Journal of Urology, 11/24/09
Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Anticancer Research, 11/16/09
Sponsor
Article Search
Sponsor